FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891604539> ?p ?o ?g. }

• W2891604539 abstract "There is still a need for new alternatives in pharmacological therapy for neglected diseases, as the drugs available show high toxicity and parenteral administration. That is the case for the treatment of leishmaniasis, particularly to the cutaneous clinical form of the disease. In this study, we present the synthesis and biological screening of eight 4-phenyl-1,3-thiazol-2-amines assayed against Leishmania amazonensis. Herein we propose that these compounds are good starting points for the search of new antileishmanial drugs by demonstrating some of the structural aspects which could interfere with the observed activity, as well as suggesting potential macromolecular targets.The compounds were easily synthesized by the methodology of Hantzsch and Weber, had their purities determined by Gas Chromatography-Mass spectrometry and assayed against the promastigote forms of Leishmania amazonensis as well as against two white cell lines (L929 and THP-1) and the monkey's kidney Vero cells. PrestoBlue® and MTT viability assays were the methodologies applied to measure the antileishmanial and cytotoxic activities, respectively. A molecular modeling target fishing study was performed aiming to propose potential macromolecular targets which could explain the observed biological behavior.Four out of the eight compounds tested exhibited important anti-promastigote activity associated with good selectivity indexes when considering Vero cells. For the most promising compound, compound 6, IC50 against promastigotes was 20.78 while SI was 5.69. Compounds 3 (IC50: 46.63 μM; SI: 26.11) and 4 (IC50: 53.12 μM; SI: 4.80) also presented important biological behavior. A target fishing study suggested that S-methyl-5-thioadenosine phosphorylase is a potential target to these compounds, which could be explored to enhance activity and decrease the potential toxic side effects.This study shows that 4-phenyl-1,3-thiazol-2-amines could be good scaffolds to the development of new antileishmanial agents. The S-methyl-5-thioadenosine phosphorylase could be one of the macromolecular targets involved in the action." @default.
• W2891604539 created "2018-09-27" @default.
• W2891604539 creator A5023286442 @default.
• W2891604539 creator A5024052083 @default.
• W2891604539 creator A5031975764 @default.
• W2891604539 creator A5040317270 @default.
• W2891604539 creator A5043861908 @default.
• W2891604539 creator A5067176043 @default.
• W2891604539 creator A5067530407 @default.
• W2891604539 creator A5079721941 @default.
• W2891604539 creator A5091550031 @default.
• W2891604539 date "2018-09-10" @default.
• W2891604539 modified "2023-10-16" @default.
• W2891604539 title "4-Phenyl-1,3-thiazole-2-amines as scaffolds for new antileishmanial agents" @default.
• W2891604539 cites W1943574546 @default.
• W2891604539 cites W1966751175 @default.
• W2891604539 cites W1973105583 @default.
• W2891604539 cites W1978651374 @default.
• W2891604539 cites W2016460939 @default.
• W2891604539 cites W2050456292 @default.
• W2891604539 cites W2055043387 @default.
• W2891604539 cites W2057389052 @default.
• W2891604539 cites W2062042038 @default.
• W2891604539 cites W2074854597 @default.
• W2891604539 cites W2076546552 @default.
• W2891604539 cites W2080738906 @default.
• W2891604539 cites W2085385568 @default.
• W2891604539 cites W2096267657 @default.
• W2891604539 cites W2104916446 @default.
• W2891604539 cites W2109582511 @default.
• W2891604539 cites W2129284802 @default.
• W2891604539 cites W2159887157 @default.
• W2891604539 cites W2160661817 @default.
• W2891604539 cites W2321044386 @default.
• W2891604539 cites W2322695360 @default.
• W2891604539 cites W2410778469 @default.
• W2891604539 cites W2415703915 @default.
• W2891604539 cites W2737761355 @default.
• W2891604539 doi "https://doi.org/10.1186/s40409-018-0163-x" @default.
• W2891604539 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6131760" @default.
• W2891604539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30214457" @default.
• W2891604539 hasPublicationYear "2018" @default.
• W2891604539 type Work @default.
• W2891604539 sameAs 2891604539 @default.
• W2891604539 citedByCount "16" @default.
• W2891604539 countsByYear W28916045392018 @default.
• W2891604539 countsByYear W28916045392019 @default.
• W2891604539 countsByYear W28916045392020 @default.
• W2891604539 countsByYear W28916045392021 @default.
• W2891604539 countsByYear W28916045392022 @default.
• W2891604539 countsByYear W28916045392023 @default.
• W2891604539 crossrefType "journal-article" @default.
• W2891604539 hasAuthorship W2891604539A5023286442 @default.
• W2891604539 hasAuthorship W2891604539A5024052083 @default.
• W2891604539 hasAuthorship W2891604539A5031975764 @default.
• W2891604539 hasAuthorship W2891604539A5040317270 @default.
• W2891604539 hasAuthorship W2891604539A5043861908 @default.
• W2891604539 hasAuthorship W2891604539A5067176043 @default.
• W2891604539 hasAuthorship W2891604539A5067530407 @default.
• W2891604539 hasAuthorship W2891604539A5079721941 @default.
• W2891604539 hasAuthorship W2891604539A5091550031 @default.
• W2891604539 hasBestOaLocation W28916045391 @default.
• W2891604539 hasConcept C109316439 @default.
• W2891604539 hasConcept C136764020 @default.
• W2891604539 hasConcept C178790620 @default.
• W2891604539 hasConcept C185592680 @default.
• W2891604539 hasConcept C202751555 @default.
• W2891604539 hasConcept C203014093 @default.
• W2891604539 hasConcept C21951064 @default.
• W2891604539 hasConcept C2776555147 @default.
• W2891604539 hasConcept C2776635100 @default.
• W2891604539 hasConcept C2777752497 @default.
• W2891604539 hasConcept C2778464347 @default.
• W2891604539 hasConcept C2780783641 @default.
• W2891604539 hasConcept C2781092759 @default.
• W2891604539 hasConcept C29730261 @default.
• W2891604539 hasConcept C41008148 @default.
• W2891604539 hasConcept C53227056 @default.
• W2891604539 hasConcept C55493867 @default.
• W2891604539 hasConcept C71240020 @default.
• W2891604539 hasConcept C71928629 @default.
• W2891604539 hasConcept C86803240 @default.
• W2891604539 hasConcept C89138240 @default.
• W2891604539 hasConcept C98274493 @default.
• W2891604539 hasConceptScore W2891604539C109316439 @default.
• W2891604539 hasConceptScore W2891604539C136764020 @default.
• W2891604539 hasConceptScore W2891604539C178790620 @default.
• W2891604539 hasConceptScore W2891604539C185592680 @default.
• W2891604539 hasConceptScore W2891604539C202751555 @default.
• W2891604539 hasConceptScore W2891604539C203014093 @default.
• W2891604539 hasConceptScore W2891604539C21951064 @default.
• W2891604539 hasConceptScore W2891604539C2776555147 @default.
• W2891604539 hasConceptScore W2891604539C2776635100 @default.
• W2891604539 hasConceptScore W2891604539C2777752497 @default.
• W2891604539 hasConceptScore W2891604539C2778464347 @default.
• W2891604539 hasConceptScore W2891604539C2780783641 @default.
• W2891604539 hasConceptScore W2891604539C2781092759 @default.
• W2891604539 hasConceptScore W2891604539C29730261 @default.
• W2891604539 hasConceptScore W2891604539C41008148 @default.
• W2891604539 hasConceptScore W2891604539C53227056 @default.

• next